Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.78 |
| ▸ | MEN1 | O00255 | 7/20 | 0.78 |
| ▸ | MAPT | P10636 | 3/20 | 0.78 |
| ▸ | POLB | P06746 | 1/20 | 0.78 |
| ▸ | BLM | P54132 | 1/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | THRA | P10827 | 1/20 | 0.65 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.63 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1028236 | 1.00 | KMT2A (0.78) | KMT2AMEN1MAPTPOLBBLM | |
| SCHEMBL10943066 | 0.91 | KMT2A (0.94) | KMT2AMEN1MAPTPOLBBLM | |
| SCHEMBL30868371 | 0.90 | KMT2A (0.88) | KMT2AMEN1MAPTPOLBBLM | |
| SCHEMBL299879 | 0.90 | KMT2A (0.88) | KMT2AMEN1MAPTPOLBBLM | |
| SCHEMBL18300094 | 0.88 | MEN1 (1.00) | KMT2AMEN1MAPTPOLBBLM | |
| SCHEMBL32690121 | 0.88 | MEN1 (1.00) | KMT2AMEN1MAPTPOLBBLM | |
| Hydrochloric Acid SCHEMBL2106899 | 0.87 | MEN1 (0.76) | KMT2AMEN1MAPTPOLBBLM | |
| SCHEMBL6795867 | 0.87 | MEN1 (0.85) | KMT2AMEN1MAPTPOLBBLM | |
| SCHEMBL1694713 | 0.86 | KMT2A (0.77) | KMT2AMEN1MAPTPOLBBLM | |
| SCHEMBL1694714 | 0.86 | KMT2A (0.77) | KMT2AMEN1MAPTPOLBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2274288-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Incyte Corporation (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | KMT2A 382/4885MEN1 1321/4885MAPT 3239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.